Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Biosimilars are not exact copies like generics for traditional small molecule drugs ... in 2023 and Janssen’s immunology medication Stelara this year, which cost about $7,000 and $10,000 ...

Biosimilars, particularly in the ustekinumab space ... 1 Fish provided an overview of the 20 small molecule drugs expected to face generic competition at some point in 2025, including those ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

"Under the IRA, which discourages the research and development of additional indications for small molecule medicines ... and Johnson & Johnson's Stelara (ustekinumab). Calling the policy a ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

Andrew McConaghie reviews the findings of the latest pharma ranking index, which assesses on the premise: if you gave the same molecule to ... rheumatoid arthritis, Stelara for psoriasis and ...